Bathing Additives in Pediatric Atopic Dermatitis

Overview

About this study

The purpose of this study is to evaluate the effectiveness of a specific and inexpensive topical approach to lowering the burden of flares in children with atopic dermatitis.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Patients from 6 months to 17 years of age.
Currently residing in US.
Follow up visits at 1 month, 3 months and 6 months after initiation of treatment in study (Figure 1).
Last follow-up at 1 year in clinic or via written mailed-out survey.
Diagnosis of atopic dermatitis AND:
- Have active signs of bacterial skin infection; OR
- Any documented suspected history of bacterial skin infection (weeping, crusting, and/or pustules on exam); OR
- Prescription for oral antibiotics for skin infection in the past 6 months from any provider); OR
- Have been prescribed bleach baths as part of an atopic dermatitis skin care regimen.

Exclusion Criteria:

Superficial skin infection without diagnosis of atopic dermatitis.
Lack of in-clinic follow up assessment at 6 months.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Megha Tollefson, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Megha Tollefson, M.D.

Closed for enrollment

More information

Publications

Patients with atopic dermatitis (AD) are prone to skin infections, with microbes such as Staphylococcus aureus suspected of contributing to pathogenesis. Bleach baths might improve AD by reducing skin microbial burden. Read More on PubMed
Staphylococcus aureus (S. aureus) colonization/infection is an important factor in the pathophysiology of atopic dermatitis (AD). Clinical trials have demonstrated conflicting efficacy of diluted bleach baths in treating moderate-to-severe AD. We conducted a double-blinded, placebo-controlled (water), cross-over trial among patients with AD to investigate the efficacy of bleach baths in reducing S. aureus colonization and AD severity. Read More on PubMed
Atopic dermatitis is a common and chronic, pruritic inflammatory skin condition that can affect all age groups. This evidence-based guideline addresses important clinical questions that arise in its management. In this second of 4 sections, treatment of atopic dermatitis with nonpharmacologic interventions and pharmacologic topical therapies are reviewed. Where possible, suggestions on dosing and monitoring are given based on available evidence. Read More on PubMed
Atopic dermatitis (AD) is a chronic, pruritic, inflammatory dermatosis that affects up to 25% of children and 2% to 3% of adults. This guideline addresses important clinical questions that arise in the management and care of AD, providing updated and expanded recommendations based on the available evidence. In this first of 4 sections, methods for the diagnosis and monitoring of disease, outcomes measures for assessment, and common clinical associations that affect patients with AD are discussed. Known risk factors for the development of disease are also reviewed. Read More on PubMed
The goals were to determine the prevalence of community-acquired methicillin-resistant Staphylococcus aureus colonization in patients with atopic dermatitis and to determine whether suppression of S aureus growth with sodium hypochlorite (bleach) baths and intranasal mupirocin treatment improves eczema severity. Read More on PubMed

Clinical Trials